OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

The KN510713 Study in Combination With mFOLFIRINOX

A phase 1/2 trial of Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX in pancreatic ductal adenocarcinoma, run by New Cancer Cure-Bio Co.,Ltd., now recruiting.